Teva sells off women’s health assets for $1.38bn
Teva has sold the remaining assets in its speciality global women’s health portfolio for $1.38 billion.
Read More
Tag: Foundation Consumer Healthcare
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
